Disease-modifying drugs in Alzheimer's disease

Drug Design, Development and Therapy
Laura GhezziDaniela Galimberti

Abstract

Alzheimer's disease (AD) is an age-dependent neurodegenerative disorder and the most common cause of dementia. The early stages of AD are characterized by short-term memory loss. Once the disease progresses, patients experience difficulties in sense of direction, oral communication, calculation, ability to learn, and cognitive thinking. The median duration of the disease is 10 years. The pathology is characterized by deposition of amyloid beta peptide (so-called senile plaques) and tau protein in the form of neurofibrillary tangles. Currently, two classes of drugs are licensed by the European Medicines Agency for the treatment of AD, ie, acetylcholinesterase inhibitors for mild to moderate AD, and memantine, an N-methyl-D-aspartate receptor antagonist, for moderate and severe AD. Treatment with acetylcholinesterase inhibitors or memantine aims at slowing progression and controlling symptoms, whereas drugs under development are intended to modify the pathologic steps leading to AD. Herein, we review the clinical features, pharmacologic properties, and cost-effectiveness of the available acetylcholinesterase inhibitors and memantine, and focus on disease-modifying drugs aiming to interfere with the amyloid beta peptide, including...Continue Reading

References

Jan 11, 1992·Lancet·D M BowenA W Procter
Oct 1, 1991·Trends in Pharmacological Sciences·J Hardy, D Allsop
Apr 16, 1986·Brain Research·P J WhitehouseK J Kellar
Jul 30, 1982·Science·R T BartusA S Lippa
Oct 18, 2000·The Cochrane Database of Systematic Reviews·J S BirksH Beppu
May 11, 2005·Neurology·S GilmanUNKNOWN AN1792(QS-21)-201 Study Team
Nov 16, 2005·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·G Stennis WatsonSuzanne Craft
Oct 19, 2006·Neuro-degenerative Diseases·Christoph KaetherHarald Steiner
Jan 25, 2007·Nature Reviews. Molecular Cell Biology·Christian Haass, Dennis J Selkoe
May 25, 2007·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Rosario Luna-MedinaAna Perez-Castillo
Mar 5, 2008·Annals of Internal Medicine·Amir QaseemUNKNOWN American College of Physicians/American Academy of Family Physicians Panel on Dementia
Nov 7, 2008·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Kim N GreenFrank M LaFerla
Apr 11, 2009·Annals of Neurology·Randall J BatemanDavid M Holtzman
Apr 17, 2009·The Cochrane Database of Systematic Reviews·Jacqueline BirksFrancesca E Holt
May 1, 2009·Expert Review of Neurotherapeutics·Taisuke Tomita
Mar 17, 2010·Neuromolecular Medicine·Vivian W ChowMarc Gleichmann
Jul 9, 2010·Lancet Neurology·Francesca MangialascheMiia Kivipelto
Apr 20, 2011·Neurology·M S RafiiUNKNOWN Alzheimer's Disease Cooperative Study
Apr 29, 2011·The British Journal of Psychiatry : the Journal of Mental Science·Orestes V ForlenzaWagner F Gattaz
May 18, 2011·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Francesca ClericiUNKNOWN Memantine Lombardy Study Group
Aug 4, 2011·Archives of General Psychiatry·Pierre N TariotUNKNOWN Alzheimer's Disease Cooperative Study Group
Nov 1, 2011·British Journal of Clinical Pharmacology·Salvatore SalomoneFilippo Drago
Dec 27, 2011·Pharmacology & Therapeutics·Haythum O TayebFrank I Tarazi
Jan 10, 2013·Journal of the Neurological Sciences·Daniela GalimbertiElio Scarpini

❮ Previous
Next ❯

Citations

Sep 23, 2014·BioMed Research International·Bernd SaletuAhsan Shoeb
Apr 12, 2016·Frontiers in Pharmacology·Lieven D DeclercqGuy Bormans
Dec 3, 2016·Scientific Reports·Shmma QuraisheAmritpal Mudher
Oct 3, 2015·Alzheimer's & Dementia : Translational Research & Clinical Interventions·Inge LuesKonrad Glund
Nov 9, 2018·Alzheimer's & Dementia : Translational Research & Clinical Interventions·Jefferson W KinneyBruce T Lamb
Dec 22, 2019·Diabetes Care·UNKNOWN American Diabetes Association
Feb 29, 2020·The Journal of Head Trauma Rehabilitation·Sarah L MartindaleJared A Rowland
Jan 27, 2017·International Psychogeriatrics·Ana Rita SilvaHorácio Firmino
Jul 29, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Agnieszka Zagórska, Anna Jaromin
Dec 12, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Zeinab Breijyeh, Rafik Karaman
May 12, 2019·International Journal of Biological Macromolecules·Ali ChaariMohamed Rholam

❮ Previous
Next ❯

Methods Mentioned

BETA
phage display

Software Mentioned

COSTELLATION

Related Concepts

Related Feeds

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Related Papers

Journal of the Neurological Sciences
Daniela GalimbertiElio Scarpini
Therapeutic Advances in Neurological Disorders
Daniela Galimberti, Elio Scarpini
Therapeutic Advances in Neurological Disorders
Konstantina G Yiannopoulou, Sokratis G Papageorgiou
Pakistan Journal of Biological Sciences : PJBS
Mervat Ibrahim Khairallah, Lobna Abdel Aal Kassem
© 2021 Meta ULC. All rights reserved